The Map of Your Diagnosis: Anatomy and Pathology
At a Glance
Anal cancer is classified by where it starts, whether it is squamous cell carcinoma or adenocarcinoma, p16 status, and TNM stage. These findings, along with lymph-node and imaging results, help clinicians choose appropriate treatment.
To understand your diagnosis, it helps to first look at the “map” of the area. While the terms might seem interchangeable, doctors use specific anatomical boundaries to decide which treatments will be most effective and how to classify the stage of the cancer.
The Anatomy of the Anal Region
Doctors divide the area into two main zones based on where the tumor started [1]:
- The Anal Canal: This is the internal tube that connects the rectum to the outside of the body. It ends at the anal verge (the opening). Tumors here are typically treated with chemoradiation [2].
- The Anal Margin (Perianal Skin): This is the skin immediately surrounding the anal opening, usually defined as being within 5 centimeters (about 2 inches) of the verge [1].
The distinction is important because very small, early-stage, well-differentiated tumors on the anal margin (often T1N0) can sometimes be safely removed with a surgery called a wide local excision, provided a clear margin can be obtained without compromising the sphincter [3]. However, if the tumor is larger, invasive, node-positive, or located in the canal, chemoradiation generally becomes the standard of care regardless of the location [2].
Understanding Your Pathology Report
When a pathologist looks at your biopsy under a microscope, they are looking for specific clues that tell them how the cancer behaves. You can use this checklist to ensure your report is complete:
1. Histologic Type (The Cell Type)
- Squamous Cell Carcinoma (SCC): This accounts for about 85% to 90% of anal cancers and is almost always linked to HPV [4]. It is highly responsive to radiation and chemotherapy [5].
- Adenocarcinoma: This is a rarer type that starts in the mucus-producing glands. It is often treated more like rectal cancer, which may involve neoadjuvant chemoradiation followed by surgery depending on the stage and location [6][7].
2. Tumor Grade
The grade (G1 through G3) describes how much the cancer cells look like healthy cells (how “differentiated” they are). A lower grade (G1) means the cells are well-differentiated, while a higher grade (G3) means they are poorly-differentiated [8]. While grade provides information about the cellular appearance, it is not the primary factor that drives standard anal SCC staging or treatment.
3. p16 Status
Your report may mention p16, a protein that serves as a surrogate marker (a proxy) for transcriptionally active high-risk HPV in the appropriate squamous tumor context [9]. Patients whose tumors are p16-positive are associated with better outcomes at a population level [9][10]. However, p16 does not guarantee an individual result, nor does a negative result change the standard chemoradiation plan. Management is driven mainly by histology, extent, and clinical factors.
How Anal Cancer is Staged (TNM)
Doctors use the AJCC TNM system to describe the extent of the cancer. Staging is typically determined by a combination of physical examination, groin-node assessment, pelvic imaging, and selected chest/abdominal imaging [11].
- T (Tumor Size and Invasion):
- N (Lymph Nodes): This identifies if the cancer has spread to nearby lymph nodes. In anal cancer, doctors pay special attention to the inguinal nodes (located in the groin). These are considered “regional” nodes, meaning they are in the immediate neighborhood of the cancer [14].
- M (Metastasis): This indicates whether the cancer has spread to distant parts of the body, such as the liver or lungs [11].
By combining these three factors, your team assigns a Stage (I through IV), which guides your specific treatment plan and helps the team understand the overall goals of your care.
Common questions in this guide
How are anal canal cancer and anal margin cancer different?
What does squamous cell carcinoma versus adenocarcinoma mean on an anal cancer report?
What does a p16-positive result mean in anal cancer?
How is anal cancer staged?
What do the T1, T2, T3, and T4 stages mean?
Get notified when new evidence is published on anus cancer.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Tumors and Tumorlike Conditions of the Anal Canal and Perianal Region: MR Imaging Findings.
Surabhi VR, Menias CO, Amer AM, et al.
Radiographics : a review publication of the Radiological Society of North America, Inc 2016; (36(5)):1339-53 doi:10.1148/rg.2016150209.
PMID: 27618320 - 2
Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Benson AB, Venook AP, Al-Hawary MM, et al.
Journal of the National Comprehensive Cancer Network : JNCCN 2018; (16(7)):852-871 doi:10.6004/jnccn.2018.0060.
PMID: 30006428 - 3
Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Benson AB, Venook AP, Al-Hawary MM, et al.
Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(6)):653-677 doi:10.6004/jnccn.2023.0030.
PMID: 37308125 - 4
Anal Squamous Intraepithelial Lesions: A Primer for Gastroenterologists.
Gioe B, Jain S, Qureshi W
Current gastroenterology reports 2025; (27(1)):71.
PMID: 41177815 - 5
Radiation Therapy for Anal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline.
Feng M, Hallemeier CL, Almada C, et al.
Practical radiation oncology 2025; (15(4)):367-386 doi:10.1016/j.prro.2025.02.001.
PMID: 40023252 - 6
Synchronous anal mucinous adenocarcinoma and anal tuberculosis presenting as chronic anal fistula: Challenging management.
Benammi S, Bakali Y, Alaoui M, et al.
Archive of clinical cases 2023; (10(2)):74-77 doi:10.22551/2023.39.1002.10245.
PMID: 37293686 - 7
Anal Adenocarcinoma: A Rare Malignancy in Need of Multidisciplinary Management.
Lukovic J, Kim JJ, Krzyzanowska M, et al.
JCO oncology practice 2020; (16(10)):635-640 doi:10.1200/OP.20.00363.
PMID: 33049179 - 8
Patterns of Care and Comparison of Outcomes Between Primary Anal Squamous Cell Carcinoma and Anal Adenocarcinoma.
Malakhov N, Kavi AM, Lee A, et al.
Diseases of the colon and rectum 2019; (62(12)):1448-1457 doi:10.1097/DCR.0000000000001506.
PMID: 31725581 - 9
HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53.
Meulendijks D, Tomasoa NB, Dewit L, et al.
British journal of cancer 2015; (112(8)):1358-66 doi:10.1038/bjc.2015.20.
PMID: 25871546 - 10
The prognostic value of HPV combined p16 status in patients with anal squamous cell carcinoma: a meta-analysis.
Sun G, Dong X, Tang X, et al.
Oncotarget 2018; (9(8)):8081-8088 doi:10.18632/oncotarget.23545.
PMID: 29487716 - 11
Staging of Anal Cancer: Role of MR Imaging.
Maas M, Tielbeek JAW, Stoker J
Magnetic resonance imaging clinics of North America 2020; (28(1)):127-140 doi:10.1016/j.mric.2019.09.005.
PMID: 31753232 - 12
MR staging of anal cancer: what the radiologist needs to know.
Golia Pernicka JS, Sheedy SP, Ernst RD, et al.
Abdominal radiology (New York) 2019; (44(11)):3726-3739 doi:10.1007/s00261-019-02020-4.
PMID: 31041496 - 13
A National-Level Validation of the New American Joint Committee on Cancer 8th Edition Subclassification of Stage IIA and B Anal Squamous Cell Cancer.
Goffredo P, Garancini M, Robinson TJ, et al.
Annals of surgical oncology 2018; (25(6)):1654-1660 doi:10.1245/s10434-018-6449-y.
PMID: 29572706 - 14
Introducing the eighth edition of the tumor-node-metastasis classification as relevant to colorectal cancer, anal cancer and appendiceal cancer: a comparison study with the seventh edition of the tumor-node-metastasis and the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma.
Shida D, Kanemitsu Y, Hamaguchi T, Shimada Y
Japanese journal of clinical oncology 2019; (49(4)):321-328 doi:10.1093/jjco/hyy198.
PMID: 30608547
This page explains anal cancer anatomy, pathology, and TNM staging for informational purposes only and does not constitute medical advice. Your oncology team should interpret your report and recommend care for your specific situation.